Avid Bioservices Inc (CDMO)

[biopharm]

Cheynew.... one can follow this chain of posts below regarding the Melanoma IST. It seems that "secondary outcomes" being measured. If Phase III Sunrise has much data that can not be disclosed till Oct 10, 2016 ==> some or much of the biomarker analysis may have rooted from the Melanoma trial so by default... the Melanoma trial data may be halted as well ??

Speaking of halted, I wonder if PPHM is in for another halt and this time-- to break free to the upside

---------------------------

North40000, given that they stopped recruitment is November, I would say the latest for the last reading would be May-end - based on the Secondary Outcomes being measured

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121890143

---------------------------

rev mon..

..
..
This Phase Ib IST was designed to assess bavituximab in combination with ipilimumab in up to 24 patients with advanced melanoma. However, due to newly approved therapies in melanoma and the changes in the standard-of-care, enrollment in the trial was recently closed by the investigator. We are currently evaluating new potential trials in melanoma based on the current standard-of-care.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121897053

--------------------------


r_m, perhaps you missed what BioBS had said earlier:

"North40000, given that they stopped recruitment in November, I would say the latest for the last reading would be May-end - based on the Secondary Outcomes being measured.
..
.
Meaning, they already have 21 weeks data on all the subjects that were enrolled"

In other words, reading, collection and analysis of data did not stop with posting of 10-Q.

http://investorshub.advfn.com/boards/replies.aspx?msg=121897053

------------------------